US regulators approved a second Covid-19 vaccine in a single week's time, greenlighting a shot developed by Moderna Inc. and the National Institutes of Health for emergency use for Americans 18 years and older.
“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” said FDA Commissioner Stephen M Hahn.
The Moderna's candidate was cleared after an expert panel of the US drug regulator overwhelmingly endorsed the mRNA based vaccine on Thursday (17 December).
The Moderna approval comes exactly a week after the US Food and Drug Administration okayed a shot from Pfizer and its German partner BioNTech. Moderna expects to have 85-100 million shots available in the US in the first three months of 2021. Vaccinations are set to begin on Monday.
The US government has ordered at least 200 million Moderna doses at a time when the country is getting hammered by the pandemic winter surge. Deaths in the US are at record highs, crossing 3,000 per day at a steady clip.
The Pfizer-BioNTech vaccine is now being administered to millions of healthcare workers and in nursing homes, which have borne the maximum burden of the US outbreak.
For Moderna, the US FDA approval is a world first. For Pfizer, the US approval came after Britain and Canada authorised nationwide use. Ongoing studies of the Moderna two-shot vaccine show more than 94 per cent effectiveness and strong protection among older adults.
America counts more than 53 million people in the category of senior citizens and 40 per cent of deaths have been in nursing homes. According to the Centers for Disease Control and Prevention, more than 100 million Americans have underlying medical conditions that put them at higher risk for severe Covid-related illness.
US Vice President Mike Pence, Second Lady Karen Pence and Surgeon General Jerome Adams all received the Pfizer-BioNTech vaccination on live TV Friday (18 December), in a bid to instill confidence among Americans.
(With inputs from IANS)
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.